Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
editorial
. 2024 Jan 31;4(1):e0002065. doi: 10.1371/journal.pgph.0002065

Dissemination and implementation of an evidence-based voluntary medical male circumcision program: The Spear & Shield program

Stephen M Weiss 1, Kasonde Bowa 2, Robert Zulu 3,4, Violeta J Rodriguez 1,5, Ryan R Cook 6, Deborah L Jones 1,*
Editor: Julia Robinson7
PMCID: PMC10830021  PMID: 38295087

Abstract

Despite compelling evidence linking voluntary medical male circumcision (VMMC) with 60–70% HIV risk reduction in sub-Saharan Africa, Zambian men have been especially reluctant to undergo VMMC. The Government of Zambia set targets for VMMC uptake and promoted community-level interventions. Spear & Shield (S&S) is an innovative, evidence-based, service program promoting VMMC uptake while ensuring both VMMC supply and demand. This study assessed the large-scale provincial rollout of the program (S&S2) utilizing the RE-AIM model for translating interventions into the community. The S&S2 study was conducted between November 2015 and December 2020, and sequentially rolled out over four Zambian provinces in 96 clinics; 24 observation clinics received VMMC training only. Local clinic healthcare workers were trained to conduct the VMMC procedure and HIV counselors were trained to lead S&S group sessions. Using the RE-AIM model, primary outcomes were: Reach, the number, proportion, and representativeness of S&S attendees; Effectiveness, the impact of S&S2 on VMMC uptake; Adoption, the number, proportion, and representativeness of clinics implementing S&S2; Implementation, fidelity to the S&S intervention manual; and Maintenance, the extent to which S&S2 became an element of standard care within community clinics. Initially, n = 109 clinics were recruited; 96 were sustained and randomized for activation (Adoption). A total of 45,630 clinic patients (n = 23,236 men and n = 22,394 women) volunteered to attend the S&S sessions (Reach). The S&S2 program ran over 2,866 clinic-months (Implementation). Although the study did not target individual-level VMMCs, ~58,301 additional VMMCs were conducted at the clinic level (Effectiveness). Fidelity to the S&S intervention by group leaders ranged from 42%-95%. Sustainability of the program was operationalized as the number of CHCs initially activated that sustained the program. Intervention delivery ended, however, when study funding ceased (Maintenance). The S&S2 program successfully utilized the RE-AIM model to achieve study goals for implementation and dissemination in four Zambian provinces. Innovative VMMC programs such as S&S2 can improve the uptake of VMMC, one of the most effective strategies in the HIV prevention arsenal.

Introduction

Voluntary medical male circumcision (VMMC) could prevent 3.4 million human immunodeficiency virus (HIV) infections in sub-Saharan Africa across a 10-year span and is an effective strategy for HIV prevention in high-prevalence populations [13]. Approximately 29.6 million VMMCs have been performed by 2020, averting 615, 000 new HIV infections. With the 29.6 million VMMCs conducted by 2020, if we stop circumcising now, 4.9 million new HIV infections will be averted by 2030 [4]. VMMC is also associated with reduced sexually transmitted infections (STIs), e.g., syphilis, human papilloma virus, cervical cancer, and urinary tract infections [1, 3, 5]. VMMC promotion began in Zambia in 2008; uptake was initially low due to lack of demand. In 2009, despite the high levels of protection from HIV associated with VMMC, ~80% of uncircumcised men in Zambia expressed no interest in undergoing VMMC [6, 7]. Models have shown that even with the scale-up of HIV treatment, VMMC remains a cost-effective, often cost-saving, prevention intervention in sub-Saharan Africa for at least the next 5 years [8].

The national promotion of VMMC in 2012 was an extended, intensive campaign designed to stimulate VMMC uptake, while ensuring VMMC supply matched demand [9]. In 2018, Zambians living with HIV numbered 1.2 million, HIV prevalence was 11.3% and 48,000 new infections were reported annually [10]. Despite high HIV prevalence, VMMC uptake in Zambia remained below 50% in many districts [11], lagging behind the President’s Emergency Plan for Acquired Immune Deficiency Syndrome (AIDS) Relief’s 80% saturation goal for priority countries [12]. Maintaining momentum during the Coronavirus Disease 2019 (COVID-19) pandemic in 2020; 227,824 men underwent VMMC and coverage increased by 15% [13]. In February 2021, 3,000,553 men in Zambia had been circumcised, representing 31% of the eligible population [11, 14]. Yet, these rates continued to fall short of the new 95% coverage goal established by the Zambian Operational Plan [15].

Behavioral change communication and demand generation, e.g., mass media and campaign materials that drive awareness and/or interest in VMMC through health promotion [11], are most effective in reaching those already contemplating VMMC [16]. Sensitization, the process through which those unaware of VMMC or its health benefits become aware [11] is the cornerstone of innovative demand generation. Suboptimal VMMC demand arises from several sources, e.g., fear of loss of sexual potency and concerns about partner preferences are key reasons to avoid VMMC [12, 17]. To stimulate VMMC demand and maximize its benefits, innovative community-level interventions are needed. The Spear & Shield (S&S) biobehavioral intervention was designed as a service program to increase VMMC uptake among Zambian men by training community health centers staff to stimulate demand through increased awareness of VMMC health benefits and safety among men and women [5, 18, 19]. The S&S randomized clinical trial targeted Zambian men from community health centers (CHCs) in the capital, Lusaka, who initially expressed no interest in undergoing VMMC. The S&S intervention consisted of four, weekly 90-minute group sessions on STIs, condom use, and VMMC; sessions utilized cognitive behavioral strategies to challenge thoughts leading to emotions that were barriers to undergoing VMMC. Men in S&S were twice as likely to undergo VMMC as the control group, and eight times more likely to undergo VMMC than the observation only condition. Men in S&S also reported greater condom use and increased sexual satisfaction [5].

Building on the S&S clinical trial, this study conducted a large-scale provincial rollout of S&S2 in Zambia, utilizing the RE-AIM implementation and dissemination framework for translating interventions into the community [20]. Specifically, the RE-AIM framework is comprised of the following components, 1) Reach: the number, proportion, and representativeness of individuals willing to participate in the program, 2) Efficacy/Effectiveness: the impact of the intervention on important outcomes such as VMMC and potential negative effects, 3) Adoption: the absolute number, proportion, and representativeness of settings or practices who are willing to incorporate the intervention into their health care delivery program, 4) Implementation: a) at the practice level, the institution’s fidelity to the core elements of a program, including consistency of delivery, and b) at the individual level, the patient’s uptake of the intervention, e.g., S&S + VMMC, and 5) Maintenance: the extent to which a program becomes institutionalized as part of routine “standard of care.” Using the RE-AIM model to achieve study goals for implementation and dissemination, S&S2 trained CHC staff to implement the S&S2 program in their CHCs [18, 19, 21] applying the Training of Trainers Model (previously described [22]). The S&S2 program was sequentially rolled out at the provincial level; our previous studies describe a series of mixed methods design studies guided by the Consolidated Framework for Implementation (CFIR) [18, 19, 21] specifically examining constructs associated with implementation outcomes (attendance). Given the RE-AIM framework, the objectives were to maximize the Reach of S&S attendees; maximize the Effectiveness of S&S by increasing the number of VMMCs; increase Adoption, defined as the number, proportion, and representativeness of clinics implementing S&S2; achieve Implementation, as defined by the fidelity to the S&S intervention manual; and Maintenance, the extent to which S&S2 became an element of standard care within community clinics. The current manuscript presents the final outcomes of the S&S2 program, describing the RE-AIM outcomes, including the circumcision rates overtime by condition in four Zambian provinces.

Methods

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 2013 Declaration of Helsinki (Fortaleza, Brazil) and its later amendments or comparable ethical standards [23]. Prior to study initiation, investigators obtained approval from the Research Ethics Committee in Zambia (University of Zambia, approval number 002-11-15), the National Health Research Authority of Zambia (NHRA001/01/06/2023) from the provincial and district leadership, and from the affiliated US Institutional Review Board (University of Miami School of Medicine, approval number 20150710).

This study includes human participants; written informed consent was obtained from all participants prior to all study activities.

Design

Adoption

The S&S2 program was conducted in Lusaka, Central, Southern, and Copperbelt Provinces. Provinces were activated sequentially over four years, enabling the implementation stage of each province to be informed by earlier provinces. As provinces were activated, provincial and district health leaders were briefed on the study objectives and procedures. Eligible Community Health Centers (CHCs) had available space for VMMC, staff to train to provide VMMC and S&S sessions, and high HIV testing service (HTS) rates, and were selected with district guidance. Thirty CHCs per province were randomized into immediate (12) and delayed (12) activation or six observation only conditions. All CHCs received VMMC supplies and VMMC training. Following province activation, in immediate activation CHCs, S&S intervention training was provided. After six months, the conclusion of the training period for immediate activation CHCs, S&S training was provided in delayed activation CHCs (see Fig 1). CHC inclusion criteria included: (1) conducting more than 50 HTS per month; (2) located in a catchment area with greater than 10,000 residents; (3) sufficient space to conduct VMMC and S&S programs; and (4) available staff to conduct VMMC and S&S services and availability for training.

Fig 1. Sequential rollout of provinces and training sequence with supervision for group leaders and VMMC training.

Fig 1

Caption. S&S = Spear & Shield.

Procedures

Randomization

Prior to randomization, CHCs were stratified by catchment population to ensure comparable sized comparisons. The randomization of CHCs for activation was conducted by Zambian investigators not affiliated with the study using a random allocation computer-generated sequence; trial statisticians did not participate in randomization. CHCs were randomized using a staged randomization procedure in each province based on the 12 largest, 6 smallest, and 12 middle-size CHCs. In stage 1, the 12 largest CHCs and the 12 middle-size CHCs were randomized with random ordering of assignment (i.e., random ordering of the immediate, delayed, and observation only conditions). In stage 2, the smallest 12 CHCs were similarly allocated to condition.

Training

S&S intervention (see also Bowa et al., 2022). Trainees were lay counselors > 18 years old engaged in HIV prevention services in the Government of Republic of Zambia. Clinics selected HTS counselors (one male, one female) to attend S&S training, plus two back-up trainees per site. Training consisted of a two-day intensive manualized workshop on the S&S intervention and study protocol, rigorous On the Job Training (OJT), and skill building to train future group leaders. Training included participatory strategies, e.g., role plays depicting real life situations that addressed myths, misconceptions and knowledge gaps on VMMC for HIV prevention [22]. Trainees then enrolled CHC attendees (i.e., three groups of 8–10 men and women) for OJT. Trainees co-led three groups of four sessions supervised by a S&S2 staff trainer: Group 1, S&S trainer conducted the session, leader observed; Group 2, session topics were divided between trainer and leader; Group 3, leader conducted sessions, trainer observed. Group leaders recruited for S&S from CHC HTS patients, the Out-Patient Department, youth friendly corners, and Maternal and Child Health services. A random sample of 10% of audio-recorded sessions were reviewed for intervention fidelity by the Zambia coordinator and a United States (US) investigator.

CHCs that had one or no VMMC providers selected two healthcare workers to train as VMMC providers per Zambian Ministry of Health VMMC guidelines. S&S2 VMMC provider trainees completed a 10-day, VMMC surgical training 3 months before the immediate S&S intervention training began. Training followed the WHO VMMC training manual and utilized the dorsal slit method as recommended by the Surgical Society of Zambia and Ministry of Health [24].

Conditions. Following Province activation, 12 CHCs randomized to the immediate intervention condition provided the S&S2 + VMMC program and 12 delayed intervention condition CHCs provided VMMC only. After 6 months, the delayed intervention condition clinics were trained to begin provision of the S&S + VMMC Program. Once implemented, CHCs continued to offer the S&S2 + VMMC program until completion of the study.

Statistical analyses

Monthly CHC-level data, i.e., numbers of persons attending the clinic undergoing HTS and the total monthly VMMCs conducted, were collected at all sites to assess the influence of the ongoing intervention on overall clinic-level VMMC uptake. Monthly CHC-level VMMC rates were modeled using mixed negative binomial regression with month, study condition, and their interaction as the main predictors of interest, controlling for province and including the (log) number of HTS as an offset term. Highly variable and nonlinear time trends in VMMC rates were modeled with cubic b-splines. CHCs were included as random intercepts in the model; although heterogeneity in CHC-specific time trends was likely, models including more complex random effects structures did not converge.

Hypotheses were tested by comparing model-predicted VMMC rates between VMMC + SS (i.e., after S&S training had been completed and sessions had been started), VMMC only (i.e., the 6-month period in CHCs randomized to the delayed condition where VMMC training and supplies were provided, but no S&S sessions or training), and observation-only conditions. Comparisons were made during two time periods, the entire study duration and the six months following study implementation. The average across the predicted monthly VMMC rates was computed within each time period, and rate ratios and confidence intervals were calculated to compare average rates across conditions. The first-six-month period was chosen to increase comparability between VMMC + SS and VMMC only conditions as the latter was active for a maximum of six months in each CHC. Several factors were likely to increase VMMC rates immediately following implementation, including newly trained, enthusiastic, and available intervention facilitators and medical professionals, adequately stocked supplies, and a cohort of men in the community eager to undergo VMMC for HIV prevention.

Measures of public health impact, including differences in absolute numbers of expected VMMCs per condition, were calculated by applying rate differences to the average number of HTS per clinic per month. Analyses were repeated in a “per-protocol” population, where clinic-months when no Spear & Shield sessions were conducted were reclassified as VMMC only. Finally, the additional impact of Spear & Shield women’s groups was estimated by splitting VMMC + SS months into those where women’s groups were active vs. those where only men’s groups were being conducted. All analyses were completed using R v.4.05 with the ‘geepack,’ ‘ggplot2,’ ‘lme4,’ ‘splines,’ and ‘emmeans’ packages.

Results

In summarizing the results, the results were presented using the RE-AIM framework. Specifically, the goals were to enhance the extent of Reach for S&S participants, improve the Effectiveness of S&S by increasing the number of VMMCs, boost Adoption by encouraging more clinics to implement S&S2 while considering the quantity, proportion, and representativeness of these clinics, ensure proper Implementation according to the S&S intervention manual and circumcision rates over time in four Zambian conditions, and promote Maintenance by integrating S&S2 as a standard practice in community clinics.

Community health center and staff characteristics

Characteristics of CHC staff (n = 385) assessed at all clinics are presented in Table 1. Table 2 presents monthly HTS and VMMC rates by study condition.

Table 1. Clinic staff characteristics (N = 385).

M (SD)
(N %)
Employed at facility (years)
0–1 year 75 (19.5%)
2–3 years 99 (25.7%)
4–5 years 69 (17.9%)
6–7 years 65 (16.9%)
8–9 years 25 (6.5%)
More than 10 years 52 (13.5%)
Job title
Physician/Clinic Officer/Sister in Charge 56 (14.5%)
Professional Nurse 103 (26.8%)
Assistant Nurse 7 (1.8%)
Counsellor 184 (47.8%)
Lay Health Worker 35 (9.1%)
Time in current position (years)
0–1 year 57 (14.8%)
2–3 years 79 (20.5%)
4–5 years 52 (13.5%)
6–7 years 67 (17.4%)
8–9 years 49 (12.7%)
More than 10 years 81 (21.0%)
Gender
Male 181 (47.0%)
Female 204 (53.0%)
Age (years) 37.37 (9.6%)
Education
Grade 8 –Grade 9 28 (7.3%)
Grade 10 10 (2.6%)
Grade 11 15 (3.9%)
Grade 12 83 (21.6%)
Diplomas/Occupational Certificates 214 (55.6%)
First Degrees/Higher Diploma 35 (9.1%)
Monthly Income (Zambian Kwacha ~ USD) 3,044.38 (2072.65)
~176.99 USD

Table 2. Observed average monthly HTS and VMMC rates by study condition, over entire study period and within the first six months of intervention implementation.

Entire study First six months
HTS VMMCs Rate HTS VMMCs Rate
VMMC + SS 853.5 101.9 0.2 535.4 102.3 .26
VMMC only 447.3 76.5 0.22 447.3 76.5 .22
Observation 553.1 63.5 0.19 311.6 44.0 .18

Note. HTS = HIV testing services. VMMC = voluntary medical male circumcision. S&S = Spear & Shield.

Community health center recruitment and activation

Adoption

Initially, k = 109 CHCs were recruited into the study, and of these k = 13 were deactivated (6 delayed and 7 immediate), leaving k = 96 activated CHCs [19]. Of these 13, k = 9 CHCs were deactivated due to failure to recruit male attendees into groups, k = 1 due to an inability to hire an MC provider, k = 1 due to limited resources, and k = 2 due to lack of interest in adopting the program. Staff retention ranged from 25–100% (Central).

Enrolment and retention in S&S groups

Reach

S&S sessions were provided as a service program during regular clinic hours with no attendee compensation; attendees received a certificate of attendance. A total of 45,630 Zambians (n = 23,236 men and n = 22,394 women) attended the S&S groups. Male attendee retention across CHCs ranged from 77% to 100% (average 94%) attending all four sessions, whereas female attendee retention ranged from 79% to 100% (average 95%).

Quality control and assurance in S&S groups

Implementation

Quality assurance evaluation of S&S groups were conducted to ensure intervention fidelity. Facilitator checklists and intervention recordings from sessions with groups 3 and 4 by the Project Manager were reviewed. A total of 256 recordings from 128 group leaders were reviewed and a score ranging from A to D (85%-100% = A, 70%-84% = B, 60%-69% = C and below 60% = D) was ascribed by study staff consensus; scores included calculating the rate of topics addressed of the intended content during sessions. Rates varied across Provinces; Lusaka Province CHCs covered 42% to 83% of intended content, Central Province CHCs covered 52% to 96% of the intended content. Southern Province rates ranged from 69% to 94%, Copperbelt rates ranged from 63% to 95%. Feedback was provided to group leaders on strengths and gaps identified or areas for improvement.

VMMC rates

Effectiveness

To evaluate the influence of the ongoing intervention on overall CHC-level VMMC uptake, the observed and model-fitted monthly CHC-level VMMC rates across study conditions were calculated. Over the entire study period, adjusted average monthly VMMC rates were 15.5, 17.3, and 12.2 per 100 HTS in VMMC + SS, VMMC only, and observation-only conditions, respectively. VMMC rates were higher in VMMC + SS (IRR = 1.27, 95% CI 1.06 to 1.53, p = .011) and VMMC only conditions (IRR = 1.42, 95% CI 1.06 to 1.91, p = .019) compared to observation only. There was no difference in VMMC rates between VMMC + SS and VMMC only (p = .4). Overall, rates were higher in the first six months of intervention implementation: 22.1, 17.3, and 13.5 per 100 HTS in VMMC + SS, VMMC only, and observation-only conditions. During this time period, VMMC + SS CHCs had higher VMMC rates than observation only (IRR = 1.63, 95% CI 1.28 to 2.08, p < .001), but there was no difference between VMMC alone and observation only (p = .09) or VMMC + SS and VMMC alone (p = .12). Results were similar in the per-protocol sample.

VMMCs attributable to the S&S intervention

CHCs performed an average of 616 HTS per month. Applying the model-predicted VMMC rates (see Fig 2), this volume of HTS implies an extra 20.3 VMMCs per month per CHC implementing VMMC training plus the S&S intervention compared to observation only. Over the 2,866 CHC-months when the S&S intervention was actively running, it resulted in an estimated 58,301 additional VMMCs performed, compared to what would be expected with no S&S intervention or VMMC training. Results over the entire study period were not compared with VMMC training alone as this condition was only active for the first six months following clinic activation. However, if VMMC rates in S&S CHCs could have been sustained at the early-implementation rate (i.e., that which occurred during the first six months), it is estimated that 53 additional VMMCs would be performed per clinic per month, or 151,938 over the study period compared to observation-only and 29 per clinic per month, or 84,802 compared to VMMC training alone.

Fig 2. VMMC rate by 100 HIV testing services performaned by condition.

Fig 2

Caption. S&S = Spear & Shield. VMMC = Voluntary Medical Male Circumcision. VCTs = Voluntary Counseling and Testing.

Impact of women’s groups

Average VMMC rates were highest during months when both S&S men’s and women’s groups were active: 15.6 per 100 HTS as compared to 12.7 with only men’s groups, 14.8 with VMMC only, and 12.2 under no intervention (observation only). The rate ratio comparing S&S + women to no intervention was modest, 1.3 (95% CI 1.05 to 1.56, p = .014), but there was no difference between S&S + women and other study conditions (Tables 3 and 4).

Table 3. Fitted average monthly VMMC rates per 100 HTS, by study condition, over entire study period and within the first six months of intervention implementation, intent-to-treat and per-protocol samples.

Entire study First six months
Rate IRR 95% CI p Rate IRR 95% CI p
Intent to treat
 VMMC + SS 15.5 1.27 (1.06, 1.53) .011 22.1 1.63 (1.28, 2.08) < .001
 VMMC only 17.3 1.42 (1.06, 1.91) .019 17.3 1.28 (0.96, 1.71) .091
 Observation 12.2 Ref 13.5 Ref
Per-protocol
 VMMC + SS 15.3 1.26 (1.04, 1.52) .021 21.6 1.6 (1.18, 2.18) .003
 VMMC only 14.8 1.21 (0.99, 1.49) .063 19.6 1.45 (1.16, 1.82) .001
 Observation 12.2 Ref 13.5 Ref

Note. HTS = HIV testing services. VMMC = voluntary medical male circumcision. S&S = Spear & Shield.

Table 4. Fitted average monthly VMMC rates per 100 HTS.

VMMC + SS months are split into those where women’s groups were conducted vs. those where only men’s groups were running.

Entire study First six months
Rate IRR 95% CI p Rate IRR 95% CI p
Intent to treat
 VMMC + SS + Women 15.6 1.28 (1.05, 1.56) .014 20.7 1.53 (1.11, 2.10) .008
 VMMC + SS 12.7 1.05 (0.78, 1.40) .76 24.8 1.83 (0.76, 4.78) .216
 VMMC only 14.8 1.21 (0.98, 1.49) .07 19.7 1.45 (1.16, 1.82) .001
 Observation 12.2 Ref 13.5 Ref

Note. Note. HTS = HIV testing services. VMMC = voluntary medical male circumcision. S&S = Spear & Shield.

Maintenance

Sustainability of the program was operationalized as the number of CHCs initially activated that sustained the program. Intervention delivery ended, however, when study funding ceased.

Discussion

This study presents the implementation and dissemination of the Spear & Shield 2 program using the RE-AIM model, building on previous research by this team [18, 19, 21, 22]. The S&S2 results indicate successful dissemination and implementation of the program across four provinces in Zambia, resulting in enhanced uptake of VMMC. Though the RE-AIM model has been used extensively in many settings, its use in Zambia has been limited, and results demonstrate the utility of the model in the Zambian context. This study thus demonstrates the successful implementation and dissemination of the S&S2 program in Zambia, using the RE-AIM model as a framework. The results indicate that S&S2 effectively reached a significant number of individuals at risk for HIV infection and resulted in increased uptake of VMMC among men. The use of the RE-AIM model in the Zambian context proved to be valuable and showcased the utility of the model in evaluating program outcomes.

S&S2 successfully reached a substantial number of men and women at risk for HIV infection and enhancing VMMC uptake among men. Within the RE-AIM model, Reach represents the number, proportion, and representativeness of the S&S2 program attendees. Attendees were CHC patients drawn from HTS and as such were representative of those in Zambia who perceived themselves as at risk of HIV infection. The program successfully engaged (Reached) over 45,000 men and women, who were representative of those in Zambia perceiving themselves at risk of HIV infection. Effectiveness of the S&S2 program on VMMC uptake at the CHC level was associated with an estimated 58,301 additional VMMCs during S&S2, compared to CHCs without S&S2, supporting previous S&S results [5]. Finally, the goal of S&S2 was to translate this efficacious intervention into a service program utilizing local, trainable talent. VMMC CHC level uptake was impacted by VMMC campaigns in each province, and the secular trend and the observation only sites within each province indicated that VMMC campaigns activated in the last 18 months of the study moderated and augmented the S&S effect. The findings also highlighted the importance of VMMC campaigns and the support of clinic leadership in enhancing VMMC rates.

Adoption in the RE-AIM model refers to the number, proportion, and representativeness of CHCs implementing the S&S2 program (VMMC+SS), whereas Implementation refers to fidelity to the S&S intervention [20]. Adoption was illustrated by the high rate of adoption (88%) among activated CHCs throughout the sequential rollout of S&S2. Adoption was also evidenced by staff engagement, such that study retention rates among staff and attendees were relatively high in three of four provinces. Implementation, evaluated as fidelity to the intervention, was partially supported, with intervention fidelity rates ranging from 42% to 96% across the provinces. Factors associated with intervention delivery identified included having less dedicated time and space to conduct the intervention due to conflicting demands within the CHC, some of which arose from other public health campaigns. Results from our previous research also suggest that the most effective delivery of the intervention relied on support from clinic leadership [18, 19, 21]. In addition, VMMC rates were exceptionally high in the 6 months to one year following activation. Both fidelity data and VMMC uptake suggest that after one year, additional “booster sessions” may be needed to improve motivation among CHC staff. Incentives for undergoing VMMC [25], women’s involvement [26] and community outreach promoting S&S after more interested candidates participate may also enhance demand for VMMC. As such, this study suggests the need for additional support, including booster sessions and incentives, to sustain motivation among clinic staff and increase demand for VMMC.

Maintenance is the extent to which S&S2 became an element of the “standard of care” within CHCs [20]. Only 12% of CHCs were unable to enroll clients or carry out group sessions and were subsequently deactivated due to failure to recruit, initiate and sustain group sessions. Even in Lusaka, the longest running province, only 5 CHCs had been deactivated by the end of the study. As such, the Maintenance of S&S2 was supported within the Zambian context. However, though CHC staff were enthusiastic and capable of achieving the goals of the intervention, the lack of modest funding to sustain the clinic personnel providing the program led to discontinuation of the S&S2 intervention at study end. Our study therefore highlights the need for ongoing efforts to institutionalize S&S2 as a standard of care in order to ensure its long-term sustainability.

This study’s results must be interpreted within the context of clinic rather than individual-level data; results reflect the VMMC outcomes from the overall clinic, not of the men attending S&S sessions. As previously found [26], VMMC rates were higher when S&S2 men’s and women’s groups were active, although not statistically significant. The original trial found women’s participation accounted for ~6% of VMMCs performed [26], which at the population level could account for a significant number of VMMCs [5]. The lack of differences in per protocol analyses may be attributable to high attendance and retention rates in men’s and women’s groups, and by the potential for women attending S&S groups to be partners of men not attending S&S. Though not evaluated, S&S may directly, rather than indirectly, benefit women participating, which may also contribute to high participation rates. Future studies may examine the impact of S&S on women and their experiences in attending S&S groups with or without a male partner.

Limitations

Concurrent with successful implementation of S&S2 in Zambia, study limitations should be considered. VMMC data were limited to CHC level monthly counts rather than individual-level data. Collecting individual-level data would have increased CHC staff burden and constricted the attendance of the 45,000 men and women. However, as the design focused on the dissemination and implementation at the CHC level, CHC staff were evaluated at the individual level, reducing CHC burden. This was an important design consideration for the already overburdened healthcare system in Zambia. However, this design did not account for potential influence of other demand creation activities happening in the area during the study period. VMMC + SS and VMMC only conditions were compared to observation-only clinics in order to account for secular trends in VMMC rates over the study period (Fig 2). However, the observation-only clinics were only a small subsample of all possible clinics in the four provinces, and other trends may not have been captured. For example, during the study period, one province initiated a campaign on a different health issue, seconding clinic staff for much of the study duration thereby reducing SS2 impact. Finally, study completion in December 2020 overlapped during the onset of the COVID-19 pandemic in Africa.

Conclusion

Overall, this study highlights the importance of translating evidence-based interventions into practice and evaluating their real-world impact. Translation of an evidence-based intervention to practice, sustaining it, and evaluating the real-world evidence produced is a lengthy, complicated process. To translate the S&S intervention, study staff trained group leaders and VMMC providers in 96 clinics. During dissemination, challenges to implementation and sustainment were addressed and study staff provided ongoing support in the field [18, 19, 21]. Nearly 3600 months of VMMC data from over 100 CHCs plus 100 years of historical VMMC data from VMMCs performed during the year prior to study commencement was collected. Although individual-level VMMC rates were not targeted, the estimated 58,301 additional VMMCs conducted at the clinic level could have reached an estimated 151,938 if VMMC rates could have been sustained at the early-implementation level. This, in and of itself, is a major contribution to the national goals in HIV prevention. The sustainability of VMMC as a public health intervention now relies on its institutionalization within the health system as a component of HIV prevention services [11]. Continued expansion of VMMC programs, such as adolescent or infant circumcision, has the potential to further reduce the burden of future illness through prevention. Effective public health service programs remain an investment in the future … today.

Supporting information

S1 Data. Clinic data.

(XLS)

S1 Checklist. Inclusivity in global research.

(DOCX)

Data Availability

Data is now available as a supplemental file.

Funding Statement

This study was funded by National Institutes of Health/National Institute of Mental Health (NIH/NIMH) (R01MH095539), awarded to, DLJ, SMW, KB, RZ, and VJR with support from the University of Miami Miller School of Medicine Center for AIDS Research funded by NIH/National Institute of Allergy and Infectious Diseases (NIAID) (P30AI073961) awarded to DLJ. VJR’s work on this study was also supported by a Ford Foundation Fellowship, administered by the National Academies of Sciences, Engineering, and Medicine (NASEM), a PEO Scholar Award from the PEO Sisterhood, and NIMH R36MH127838. The funding agencies were not involved in the writing of this manuscript or the decision to submit.

References

  • 1.Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298. doi: 10.1371/journal.pmed.0020298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643–56. doi: 10.1016/S0140-6736(07)60312-2 [DOI] [PubMed] [Google Scholar]
  • 3.Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–66. doi: 10.1016/S0140-6736(07)60313-4 [DOI] [PubMed] [Google Scholar]
  • 4.UNAIDS Joint United Nations Programme on HIV/AIDS, World Health Organization. Uneven progress on the voluntary medical male circumcision. 2022.
  • 5.Weiss SM, Zulu R, Jones DL, Redding CA, Cook R, Chitalu N. The Spear and Shield intervention to increase the availability and acceptability of voluntary medical male circumcision in Zambia: a cluster randomised controlled trial. Lancet HIV. 2015;2(5):e181–e9. doi: 10.1016/S2352-3018(15)00042-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Central Statistical Office (CSO); Ministry of Health (MOH); University of Zambia. MEASURE Evaluation. Zambia Sexual Behaviour Survey 2009. Lusaka, Zambia. 2010.
  • 7.Tobian AAR, Gray RH. The medical benefits of male circumcision. JAMA. 2011;306(13):1479–80. doi: 10.1001/jama.2011.1431 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bansi-Matharu L, Mudimu E, Martin-Hughes R, Hamilton M, Johnson L, Ten Brink D, et al. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Global Health. 2023;11(2):e244–e55. doi: 10.1016/S2214-109X(22)00515-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Republic of Zambia. National Voluntary Medical Male Circumcision (VMMC) Communication and Advocacy Strategy 2012–2015. In: Health Mo, editor. Lusaka, Zambia. 2012.
  • 10.Avert. HIV and AIDS in Zambia 2021 [https://www.avert.org/global-hiv-and-aids-statistics.]
  • 11.Zambia Statistics Agency ZMoH, & ICF. Zambia Demographic and Health Survey 2018. In: Zambia Statistics Agency MoH, and ICF, editor. 2019.
  • 12.Council NA. Zambia country report. Monitoring the declaration of commitment on HIV and AIDS and the universal access. 2013.
  • 13.USAID. Voluntary Male Circumcision. 2021.
  • 14.Chulu K. Over 3 million circumcised in Zambia. Zambia Daily Mail. 2021.
  • 15.Republic of Zambia Ministry of Health. National Operational Plan: For a Sustained Voluntary Medical Male Circumcision Programme in Zambia. 2021.
  • 16.Redding CA, Jones D, Zulu R, Chitalu N, Cook R, Weiss SM. Stages of Change for Voluntary Medical Male Circumcision and Sexual Risk Behavior in Uncircumcised Zambian Men: The Spear and Shield Project. Inter J Behav Med. 2015;22(6):799–806. doi: 10.1007/s12529-015-9485-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hewett PC, Haberland N, Apicella L, Mensch BS. The (mis) reporting of male circumcision status among men and women in Zambia and Swaziland: a randomized evaluation of interview methods. PLoS ONE. 2012;7(5):e36251. doi: 10.1371/journal.pone.0036251 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Jones DL, Rodriguez VJ, Butts SA, Arheart K, Zulu R, Chitalu N, et al. Increasing acceptability and uptake of voluntary male medical circumcision in Zambia: implementing and disseminating an evidence-based intervention. Transl Behav Med. 2018;8(6):907–916. doi: 10.1093/tbm/iby078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rodriguez VJ, Chahine A, de la Rosa A, Lee TK, Cristofari NV, Jones DL, et al. Identifying factors associated with successful implementation and uptake of an evidence-based voluntary medical male circumcision program in Zambia: the Spear and Shield 2 Program. Trans Behav Med. 2020;10(4):970–977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Glasgow RE, Lichtenstein E, Marcus AC. Why don’t we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition. Am J Public Health. 2003;93(8):1261–7. doi: 10.2105/ajph.93.8.1261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cristofari NV, Rodriguez VJ, Jones DL, Weiss SM. Understanding barriers and facilitators to voluntary medical male circumcision and Spear and Shield uptake in Zambian community health centers. Trans Behav Med. 2022;12(5):613–621. doi: 10.1093/tbm/ibac007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Bowa K, Rodriguez VJ, Malik FS, Knight J, Cristofari N, Parrish MS, et al. Dissemination of the Spear & Shield Project using a Training of Trainers Model: A reflection on challenges and successes. Transl Behav Med. 2022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. doi: 10.1001/jama.2013.281053 [DOI] [PubMed] [Google Scholar]
  • 24.World Health Organization. Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics: recommendations and key considerations. 2020. [PubMed]
  • 25.Choko AT, Candfield S, Maheswaran H, Lepine A, Corbett AL, Fielding K. The effect of demand-side financial incentives for increasing linkage into HIV treatment and voluntary medical male circumcision: a systematic review and meta-analysis of randomised controlled trials in low-and middle-income countries. PLoS ONE. 2018;13(11):e0207263. doi: 10.1371/journal.pone.0207263 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Cook R, Jones D, Redding CA, Zulu R, Chitalu N, Weiss SM. Female Partner Acceptance as a Predictor of Men’s Readiness to Undergo Voluntary Medical Male Circumcision in Zambia: The Spear and Shield Project. AIDS Behav. 2016;20(11):2503–13. doi: 10.1007/s10461-015-1079-x [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0002065.r001

Decision Letter 0

Jonathan Huang

19 May 2023

PGPH-D-23-00137

Dissemination and implementation of an evidence-based voluntary medical male circumcision program: The Spear & Shield Program

PLOS Global Public Health

Dear Dr. Jones,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 03 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Jonathan Huang

Academic Editor

PLOS Global Public Health

Journal Requirements:

1. Please include information in the Methods section on type of consent obtained, and whether the IRBs approved the consent procedures." 2) “Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

2. Please provide separate figure files in .tif or .eps format.

For more information about figure files please see our guidelines:  LINK

https://journals.plos.org/globalpublichealth/s/figures 

https://journals.plos.org/globalpublichealth/s/figures#loc-file-requirements 

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: I don't know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is a very interesting manuscript describing the scale up of VMMC in 4 provinces of Zambia using the S&S and RE-AIM framework. In each province, clinic were divided into immediate (12), delayed (12) and observation groups (6) regarding VMMC (observation) and S&S (immediate and delayed). Result shows an increase of VMMC in the immediate clinics.

General: Clarity and organization of the paper can be improved to easy understanding. Write in full first time an acronym is used. review typos and totals.

Specific:

Methods

Ethics

1. Please considered a reference to the last version of the "Declaration of Helsinki 2013, Fortaleza, Brazil"

2. Please specify "written or oral consent"?

Procedures

1."conditions" and "Training" on 2nd and 3rd paragraphs respectively seem dislocated.

2. "Trainees were GRZ lay counselors" please review sentence.

Results

1. Says "N= 310", Actual sum =385

2. Table 1 : Please reorganize: "Employment at facilite (years)" - Less than 1 year, [2-3] etc,

3. Table 1: Be clear on what is presented: Age in years (mean, Median, SD, IQR)

4. Table 1: Be clear on what is presented: Monthly income in USD/ZK (mean, Median, SD, IQR)

5. Tabel 1: Include all acronyms in full in the figure legend caption

6. Ranges provided (average) > This is not clear - Mean or medium?

7. Figures need legends captions

Discussion

1. Focus on results of this study not only the potential results.

Reviewer #2: Thank you for this opportunity to review this interesting article titled" Dissemination and implementation of an evidence-based voluntary medical male circumcision program: The Spear & Shield Program". The manuscript is technically sound and reaches a conclusion that is consistent with previous research. The study adds significant value to the global efforts aiming to contain HIV infections. Nonetheless, data supporting findings are required to be attached or deposited to a public repository.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0002065.r003

Decision Letter 1

Jianhong Zhou

14 Jul 2023

PGPH-D-23-00137R1

Dissemination and implementation of an evidence-based voluntary medical male circumcision program: The Spear & Shield Program

PLOS Global Public Health

Dear Dr. Jones,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 26 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Jianhong Zhou

Staff Editor

PLOS Global Public Health

Journal Requirements:

1. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

2. Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.

a. State the initials, alongside each funding source, of each author to receive each grant.

b. If any authors received a salary from any of your funders, please state which authors and which funders.

If you did not receive any funding for this study, please simply state: “The authors received no specific funding for this work.”

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: (No Response)

Reviewer #4: (No Response)

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #3: (No Response)

Reviewer #4: No

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #3: (No Response)

Reviewer #4: I don't know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #3: (No Response)

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: (No Response)

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #3: 1. Introduction needs updating.

Close to 30M VMMC had been performed by 2020, averting 615, 000 new HIV infections. With the 29.6M VMMC conducted by 2020, if we stop circumcising now, 4.9 M new HIV infections will be averted by 2030 (Uneven progress on the voluntary medical male circumcision. Programme across 15 eastern and southern African countries in the face of the COVID-19 pandemic. Geneva: UNAIDS & WHO; 2022).

Recently, at AIDS Impact, # of VMMC was reported to be >30M and even more new infections averted? (contact zembel@unaids.org for latest figures).

Models have shown that VMMC remains a cost-effective, often cost-saving, prevention intervention in sub-Saharan Africa for at least the next 5 years (Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Glob Health. 2023). Concerns were whether it was still effective given scale-up of HIV treatment (for prevention and treatment) programs).

2. Ethical approval - include approvals numbers (e.g. Prior to study initiation, investigators obtained approval from the Research Ethics Committee in Zambia (University of Zambia, #XXX), from the provincial and district leadership, and from the affiliated US Institutional Review Board (University of Miami, #YYY).

3. Minor edits

Innovative VMMC programs such as S&S2 can improve the uptake VMMC, of one of the most...?

VMMC program until completion of the study (no full stop).

Reviewer #4: Summary

The manuscript describes the programmatic roll out of interventions derived from the Spear and Shield (S & S) clinical trial to four provinces in Zambia. S&S intervention was associated with increased likelihood to of circumcision uptake and higher rate of condom use. Its programmatic roll out was implemented from Nov 2015 to December 2020 to promote uptake of VMMC. Authors assessed the roll out using RE-AIM model to measure VMMC reach, uptake, and other attributes of program performance. They reported an increase in number of circumcisions at clinic level and concluded that the program successfully utilized the RE-AIM model to achieve study goals for implementation and dissemination.

General comments:

The manuscript raises important considerations for improving VMMC program update by matching demand creation with service availability. It however requires edits to improve clarity of the link Objectives, methods, results and conclusions. It would be helpful to start by crystalizing the objectives.

Specific Comments

Abstract:

The results do not clearly show how the RE-AIM model helped achieve the study goals for implementation and dissemination as stated in the conclusion. The authors should edit the abstract to show a clear link between objectives, RE-AIM Model, results and conclusion. The results of assessing the VMMC program roll out against each element of RE-AIM framework should be made clearer.

Statistical analysis

A found it difficult to align the different fragmentations of the analysis with the objectives and the RE AIM framework. I am not sure if it can be simplified for the readers.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0002065.r005

Decision Letter 2

Steve Zimmerman

7 Nov 2023

PGPH-D-23-00137R2

Dissemination and implementation of an evidence-based voluntary medical male circumcision program: The Spear & Shield Program

PLOS Global Public Health

Dear Dr. Jones,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

All of the reviewers are satisfied that your revisions have dealt with the concerns they raised earlier in the review process.

However, there is one request in the original decision letter that is still outstanding:

Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

Please submit your revised manuscript by Dec 07 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Steve Zimmerman, PhD

PLOS Staff Editor

Journal Requirements:

1. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

2. Please include information in the Methods section on type of consent obtained, and whether the IRBs approved the consent procedures." 2) “Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

Reviewer #4: All comments have been addressed

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #3: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: All comments have been addressed.

Reviewer #4: No further comments

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0002065.r007

Decision Letter 3

Julia Robinson

20 Dec 2023

Dissemination and implementation of an evidence-based voluntary medical male circumcision program: The Spear & Shield Program

PGPH-D-23-00137R3

Dear Dr. Jones,

We are pleased to inform you that your manuscript 'Dissemination and implementation of an evidence-based voluntary medical male circumcision program: The Spear & Shield Program' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Julia Robinson

Staff Editor

PLOS Global Public Health

***********************************************************

Reviewer Comments (if any, and for reference):

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data. Clinic data.

    (XLS)

    S1 Checklist. Inclusivity in global research.

    (DOCX)

    Attachment

    Submitted filename: SS2 Main Paper RR.docx

    Attachment

    Submitted filename: RR SS2 Main Paper.docx

    Attachment

    Submitted filename: Response to Reviewers 11.27.docx

    Data Availability Statement

    Data is now available as a supplemental file.


    Articles from PLOS Global Public Health are provided here courtesy of PLOS

    RESOURCES